Muhlenkamp & Co’s Thermo Fisher Scientific TMO Stock Holding History

Muhlenkamp & Co’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-450	Closed	-$228K	–	32
2023 Q3	$228K	Buy	+450	New	+$240K	0.08%	31

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Muhlenkamp & Co's TMO Position: Q4 2023 in Review

Muhlenkamp & Co sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 450 shares — an estimated $228K sold.

Muhlenkamp & Co first reported a position in TMO in Q3 2023 and held it in 1 quarter. The position peaked at $228K in Q3 2023. 2,487 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

Muhlenkamp & Co reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
Muhlenkamp & Co sold 450 Thermo Fisher Scientific shares in Q4 2023, an estimated $228K.
Muhlenkamp & Co first reported a position in Thermo Fisher Scientific in Q3 2023 and held it in 1 quarter.
Muhlenkamp & Co's Thermo Fisher Scientific position peaked at $228K in Q3 2023.
2,487 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on Muhlenkamp & Co's 13F filing for Q4 2023, filed 8 Jan 2024.